Adjuvant cemiplimab therapy for patients with resected cutaneous squamous-cell carcinoma (cSCC) significantly decreased recurrence rates, achieving disease-free survival rates of 87% compared to 64% with placebo over 24 months. This phase 3 trial, involving 415 patients, found that cemiplimab reduced both locoregional and distant recurrence. Adverse events were noted in 24% of cemiplimab patients versus 14% in the placebo group, with serious immune-related adverse events being more common. Ongoing monitoring of overall survival is crucial as data remain immature.

Source: New England Journal of Medicine